In 1866, the 26-year-old pharmacist Dr. Willmar Schwabe laid the cornerstone for the success of his company: he founded a "manufacturing facility for dispensing medicines." His goal was to research and produce premium medicines at a standardised and consistent quality.
Dr. Schwabe published his Pharmacopoeia Homoeopathica Polyglottica in German, English and French. This reference work was the predecessor of what is now the Homeopathic Pharmacopoeia and the homeopathic section of the European Pharmacopoeia (Ph. Eur.).
In the same year, a witch-hazel extract was first marketed as a phytopharmaceutical product. Over time it evolved into Hametum® ointment.
The company, which had grown to a staff of 300 employees, moved into a new facility in the Paunsdorf neighbourhood of Leipzig. Greenhouses and fields for medicinal plants were also established there. By that time, Schwabe was present all around the globe, including the Indian subcontinent as well as the Transvaal (now part of South Africa), Brazil and Mexico.
The hawthorn-leaf product Crataegutt® was marketed. It contained a standardised hawthorn extract and served as a pioneer in terms of how research was conducted on other herbal special extracts.
Especially at its new site in Karlsruhe-Durlach, from 1945 onward the company focussed more and more on research and development of phytopharmaceuticals which fulfilled the standards of western medicine. In the years that followed, Schwabe built new buildings for administration, research and production.
Deutsche Homöopathie-Union (DHU) was established as the only independent company within the Schwabe Group. To this day it specialises in developing, manufacturing and distributing homeopathic drugs. The company Dr. Willmar Schwabe Arzneimittel concentrated on research and development of phytopharmaceuticals.
Tebonin® liquidum was marketed. It was followed in 1967 by Tebonin® film-coated tablets as well as Tebonin® sustained-release film-coated tablets. The ginkgo special extract EGb 761® in Tebonin® is now considered the world's most thoroughly researched and best-documented herbal extract.
At a site near Karlsruhe, Schwabe began organically growing the medicinal plants needed to manufacture its proprietary products. Terra Medica, as the area is called, has been organically certified since 1998.
Dr. Klaus-Peter Schwabe, a trained biochemist, and Dr. Wolf-Dietrich Schwabe, who studied business, became members of the company's senior management in 1976 and 1977. In 1986, Norbert Keller was appointed to the executive board as well. From that time onward, Dr. Willmar Schwabe Arzneimittel gradually became today's globally active Schwabe Group by founding companies as well as acquiring other businesses and becoming shareholders.
In 2003, the Schwabe Group's portfolio expanded horizontally. The business sectors of phytopharmaceuticals and homeopathic drugs grew to include premium-quality nutritional supplements.
In 2004, Dr. Dirk Reischig took on management of the Schwabe Group. Dr. Klaus-Peter Schwabe, Dr. Wolf-Dietrich Schwabe and Norbert Keller were appointed to the advisory board. Additional growth in sales occurred, and more foreign investments are made. The Schwabe Group gained more and more international relevance.
Since 1 May 2016, Olaf Schwabe has been the head of the Schwabe Group, representing the fifth generation of the family. As the chief executive officer, he is one of the five-member Group Executive Team which is responsible for business operations at the Schwabe Group and defines their global strategy.
By late 2016, the Schwabe Group had achieved sales of €900 million. The Schwabe Group currently employs around 3,600 people worldwide.